Paper36765019
Efficacy of the Glucagon-Like Peptide-1 Receptor Agonists Liraglutide and Semaglutide for the Treatment of Weight Regain After Bariatric surgery: a Retrospective Observational Study.
Jensen AB and 6 others. Obes Surg, 2023. Cited by 142 papers, by iCite.
Cite this record
ConductScience Library. Efficacy of the Glucagon-Like Peptide-1 Receptor Agonists Liraglutide and Semaglutide for the Treatment of Weight Regain After Bariatric surgery: a Retrospective Observational Study. Papers, record 36765019. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/36765019
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Efficacy of the Glucagon-Like Peptide-1 Receptor Agonists Liraglutide and Semaglutide for the Treatment of Weight Regain After Bariatric surgery: a Retrospective Observational Study.
- PubMed
Topics11
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Bariatric Surgery | Major topic |
| Diabetes Mellitus, Type 2 | Major topic |
| Obesity, Morbid | Major topic |
| Female | |
| Humans | |
| Male | |
| Glucagon-Like Peptide-1 Receptor | |
| Hypoglycemic Agents | |
| Liraglutide | |
| Weight Gain | |
| Semaglutide |
Source PubMed
Trials1
The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.
| Trial | Title | The trial lists it as | Named in the paper's record |
|---|---|---|---|
| NCT06132477 | Impact GLP-1 Agonists Following Bariatric | Background |
Source ClinicalTrials.gov
References25
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 31677016 | Definitions of Long-Term Weight Regain and Their Associations with Clinical Outcomes. | Obes Surg | 2020 | https://conductscience.org/library/papers/31677016 | PubMed |
| 2 | 32870301 | Benefits and Risks of Bariatric Surgery in Adults: A Review. | JAMA | 2020 | https://conductscience.org/library/papers/32870301 | PubMed |
| 3 | 33392999 | Multidisciplinary Approach for Weight Regain-how to Manage this Challenging Condition: an Expert Review. | Obes Surg | 2021 | https://conductscience.org/library/papers/33392999 | PubMed |
| 4 | 30058859 | Current concepts in management of weight regain following bariatric surgery. | Expert Rev Endocrinol Metab | 2018 | https://conductscience.org/library/papers/30058859 | PubMed |
| 5 | 27295427 | Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. | N Engl J Med | 2016 | https://conductscience.org/library/papers/27295427 | PubMed |
| 6 | 27633186 | Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. | N Engl J Med | 2016 | https://conductscience.org/library/papers/27633186 | PubMed |
| 7 | 31422062 | Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. | Lancet Diabetes Endocrinol | 2019 | https://conductscience.org/library/papers/31422062 | PubMed |
| 8 | 18996762 | Synergistic weight loss and diabetes resolution with exenatide administration after laparoscopic gastric banding. | Surg Obes Relat Dis | 2009 | https://conductscience.org/library/papers/18996762 | PubMed |
| 9 | 27256860 | Effectiveness and tolerability of liraglutide in patients with type 2 diabetes mellitus and obesity after bariatric surgery. | Surg Obes Relat Dis | 2016 | https://conductscience.org/library/papers/27256860 | PubMed |
| 10 | 30022424 | Efficacy of High-Dose Liraglutide as an Adjunct for Weight Loss in Patients with Prior Bariatric Surgery. | Obes Surg | 2018 | https://conductscience.org/library/papers/30022424 | PubMed |
| 11 | 30768836 | Routine clinical use of liraglutide 3 mg for the treatment of obesity: Outcomes in non-surgical and bariatric surgery patients. | Diabetes Obes Metab | 2019 | https://conductscience.org/library/papers/30768836 | PubMed |
| 12 | 31362076 | Liraglutide 3mg as a weight-loss strategy after failed bariatric surgery in a patient with hypothalamic obesity following craniopharyngioma. | Diabetes Metab | 2020 | https://conductscience.org/library/papers/31362076 | PubMed |
| 13 | 34212346 | Initial Experience with Alternate-Day Liraglutide for Weight Regain Following Bariatric Surgery. | Obes Surg | 2021 | https://conductscience.org/library/papers/34212346 | PubMed |
| 14 | 35060021 | Effectiveness and Safety of Liraglutide in Managing Inadequate Weight Loss and Weight Regain after Primary and Revisional Bariatric Surgery: Anthropometric and Cardiometabolic Outcomes. | Obes Surg | 2022 | https://conductscience.org/library/papers/35060021 | PubMed |
| 15 | 31174993 | Adjunctive liraglutide treatment in patients with persistent or recurrent type 2 diabetes after metabolic surgery (GRAVITAS): a randomised, double-blind, placebo-controlled trial. | Lancet Diabetes Endocrinol | 2019 | https://conductscience.org/library/papers/31174993 | PubMed |
| 16 | 33492629 | Use of Weight Loss Medications in Patients after Bariatric Surgery. | Curr Obes Rep | 2021 | https://conductscience.org/library/papers/33492629 | PubMed |
| 17 | 26132939 | A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management. | N Engl J Med | 2015 | https://conductscience.org/library/papers/26132939 | PubMed |
| 18 | 28110911 | Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1): a double-blind, randomised, placebo-controlled, parallel-group, multinational, multicentre phase 3a trial. | Lancet Diabetes Endocrinol | 2017 | https://conductscience.org/library/papers/28110911 | PubMed |
| 19 | 33567185 | Once-Weekly Semaglutide in Adults with Overweight or Obesity. | N Engl J Med | 2021 | https://conductscience.org/library/papers/33567185 | PubMed |
| 20 | 33652862 | Do Gut Hormones Contribute to Weight Loss and Glycaemic Outcomes after Bariatric Surgery? | Nutrients | 2021 | https://conductscience.org/library/papers/33652862 | PubMed |
Cited by94
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 142 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42720874 | Adipose Tissue Remodeling Beyond Weight Loss: New Insights Into Incretin-Based Therapies and Bariatric Surgery. | Curr Obes Rep | 2026 | https://conductscience.org/library/papers/42720874 | PubMed |
| 42718598 | Use of incretin receptor agonists in patients submitted to metabolic bariatric surgery - a systematic review and meta-analysis. | Front Endocrinol (Lausanne) | 2026 | https://conductscience.org/library/papers/42718598 | PubMed |
| 42716982 | Anesthetic Safety and Perioperative Outcomes in GLP-1 Receptor Agonist-Treated Patients Undergoing Lipoabdominoplasty. | Aesthetic Plast Surg | 2026 | https://conductscience.org/library/papers/42716982 | PubMed |
| 42666183 | Clinical efficacy of tirzepatide for weight regain and suboptimal glycemic control following laparoscopic sleeve gastrectomy: a case series of three patients with obesity-associated type 2 diabetes. | Front Endocrinol (Lausanne) | 2026 | https://conductscience.org/library/papers/42666183 | PubMed |
| 42661796 | Weight Recurrence After Bariatric Surgery: Incretin-Based Therapies and the Evolving Role of Revisional Surgery. | Cureus | 2026 | https://conductscience.org/library/papers/42661796 | PubMed |
| 42608458 | Normal dopamine uptake ratio on [18F]FDOPA pet-imaging in obesity. | Int J Obes (Lond) | 2026 | https://conductscience.org/library/papers/42608458 | PubMed |
| 42471527 | Optimal Timing of GLP-1 Receptor Agonist Initiation in Patients with Obesity Eligible for Metabolic Bariatric Surgery. | Obes Surg | 2026 | https://conductscience.org/library/papers/42471527 | PubMed |
| 42446801 | Optimal Timing for Initiating Liraglutide 3.0 mg in Patients With Persistent Obesity Six Months After Metabolic and Bariatric Surgery. | Obes Surg | 2026 | https://conductscience.org/library/papers/42446801 | PubMed |
| 42382138 | Weight loss and cardiovascular outcomes with incretin-based therapies after metabolic and bariatric surgery: a nationwide US cohort study. | EClinicalMedicine | 2026 | https://conductscience.org/library/papers/42382138 | PubMed |
| 42334596 | Adjunctive use of glucagon-like peptide-1 receptor agonists after bariatric surgery: updated systematic review and meta-analysis of randomized controlled trials. | Acta Diabetol | 2026 | https://conductscience.org/library/papers/42334596 | PubMed |
| 42274840 | Refining the Bariatric Journey: A Proposed Neoadjuvant and Adjuvant Framework for GLP-1 Receptor Agonists Inspired by Oncology. | Curr Obes Rep | 2026 | https://conductscience.org/library/papers/42274840 | PubMed |
| 42265997 | 2026 AHA/ACC/ADA/ASN Guideline for the Prevention, Detection, Evaluation, and Management of Cardiovascular-Kidney-Metabolic Syndrome: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. | J Am Coll Cardiol | 2026 | https://conductscience.org/library/papers/42265997 | PubMed |
| 42225949 | The impact of adjuvant anti-obesity medications on 10-year weight loss outcomes after sleeve gastrectomy. | Int J Obes (Lond) | 2026 | https://conductscience.org/library/papers/42225949 | PubMed |
| 42160228 | Initiation of GLP-1 Receptor Agonists Treatment after Bariatric Metabolic Surgery and Major Adverse Cardiac Events. | Obes Facts | 2026 | https://conductscience.org/library/papers/42160228 | PubMed |
| 42154211 | Ring-Augmented Versus Standard Roux-en-Y Gastric Bypass: A Systematic Review and Meta-Analysis of Randomized Controlled Trials with GRADE Assessment. | Obes Surg | 2026 | https://conductscience.org/library/papers/42154211 | PubMed |
| 42124784 | GLP-1 Receptor Agonist Combination Therapy Before and After Metabolic and Bariatric Surgery: A Review of Outcomes. | J Metab Bariatr Surg | 2026 | https://conductscience.org/library/papers/42124784 | PubMed |
| 42010688 | Mechanisms of weight recurrence after bariatric surgery. | Nutr Metab (Lond) | 2026 | https://conductscience.org/library/papers/42010688 | PubMed |
| 41977175 | Disproportionality Analysis of Tirzepatide vs. Semaglutide and Liraglutide: System Organ Class-Level Post-Marketing Reporting Patterns in EudraVigilance. | Int J Mol Sci | 2026 | https://conductscience.org/library/papers/41977175 | PubMed |
| 41824845 | GLP-1 receptor agonists for weight loss: A systematic review and meta-analysis of randomized controlled trials. | Medicine (Baltimore) | 2026 | https://conductscience.org/library/papers/41824845 | PubMed |
| 41821791 | Gaps in obesity management in the UAE and the role of bariatric endoscopy. | Front Gastroenterol (Lausanne) | 2023 | https://conductscience.org/library/papers/41821791 | PubMed |
Genes3
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| GIP | 2695 | PubTator's text mining | https://conductscience.org/library/genes/2695 | NCBI Gene |
| GLP1R | 2740 | PubTator's text mining | https://conductscience.org/library/genes/2740 | NCBI Gene |
| INS | 3630 | PubTator's text mining | https://conductscience.org/library/genes/3630 | NCBI Gene |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/36765019
GET https://conductscience.org/api/papers/v1/36765019/references?page=2